Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

97591eeb-89dc-4b70-92d4-2bb70d263098

—

4a7a802a-ffaa-5952-881a-737c62af7165

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • CHOLESTEROL_HOMEOSTASIS+0.400
  • E2F_TARGETS+0.400
  • G2M_CHECKPOINT+0.400
  • MTORC1_SIGNALING+0.400
  • MYC_TARGETS_V1+0.400
  • GLYCOLYSIS+0.300
  • MITOTIC_SPINDLE+0.300
  • SPERMATOGENESIS+0.300
  • ANDROGEN_RESPONSE+0.200
  • FATTY_ACID_METABOLISM+0.200

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.500
  • INTERFERON_ALPHA_RESPONSE-0.500
  • INTERFERON_GAMMA_RESPONSE-0.500
  • INFLAMMATORY_RESPONSE-0.300
  • APOPTOSIS-0.200
  • COMPLEMENT-0.200
  • IL2_STAT5_SIGNALING-0.200
  • IL6_JAK_STAT3_SIGNALING-0.200
  • KRAS_SIGNALING_DN-0.200
  • KRAS_SIGNALING_UP-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-77-6845-01A-11R-1949-07
lung-landscapes@6
—cohortSQ20.885
2SRR4296106
lung-landscapes@6
—cohortSQ10.840
3a1539e2f-42d6-4314-9ea0-e29635d9e76f
colon-landscapes@1
——0.834
4SRR10900595
melanoma-umap@29
——0.826
5TCGA-CN-6997-01A-11R-2016-07
head-neck@1
——0.826
6TCGA-E2-A14V-01A-11R-A12D-07
breast-umap@18
—C0.825
7TCGA-DQ-5629-01A-01R-1873-07
head-neck@1
——0.824
8TCGA-BT-A20N-01A-11R-A14Y-07
bladder-landscape@3
——0.822
9SRR8518424
breast-umap@18
—C0.818
10TCGA-22-4591-01A-01R-1201-07
lung-landscapes@6
—cohortSQ10.814

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
CHOLESTEROL_HOMEOSTASIS0.400Remibrutinib— uncovered
E2F_TARGETS0.400Inavolisib— uncovered
G2M_CHECKPOINT0.400Inavolisib— uncovered
MTORC1_SIGNALING0.400Inavolisib— uncovered
MYC_TARGETS_V10.400Inavolisib— uncovered
GLYCOLYSIS0.300Inavolisib— uncovered
MITOTIC_SPINDLE0.300Inavolisib— uncovered
SPERMATOGENESIS0.300Inavolisib— uncovered
ANDROGEN_RESPONSE0.200Inavolisib— uncovered
FATTY_ACID_METABOLISM0.200Inavolisib— uncovered
HYPOXIA0.200Idelalisib— uncovered
MYC_TARGETS_V20.200Idelalisib— uncovered
ADIPOGENESIS0.100Inavolisib— uncovered
BILE_ACID_METABOLISM0.100Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.100Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.100Idelalisib— uncovered
HEDGEHOG_SIGNALING0.100Inavolisib— uncovered
PEROXISOME0.100Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.100Idelalisib— uncovered
UV_RESPONSE_DN0.100Inavolisib— uncovered